Last reviewed · How we verify

Gestovis — Competitive Intelligence Brief

Gestovis (pentagestrone acetate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: pentagestrone acetate. Area: Other.

unknown pentagestrone acetate Other Live · refreshed every 30 min

Target snapshot

Gestovis (pentagestrone acetate). Pentagestrone acetate is a progestin that works by binding to progesterone receptors in the body, mimicking the effects of the natural hormone progesterone.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Gestovis TARGET pentagestrone acetate unknown pentagestrone acetate

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (pentagestrone acetate class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gestovis — Competitive Intelligence Brief. https://druglandscape.com/ci/pentagestrone-acetate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing